Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows

Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows
Decipher Bioscience's proprietary artificial intelligence platform, Decipher GRID, one of the world's largest urologic cancer genomic databases, can be used to identify subtypes of prostate cancer and predict which men may benefit from treatment with chemotherapy, according to clinical data using the technology. Its use helped determine that men newly diagnosed with a specific subtype of metastatic hormone-sensitive prostate cancer (mHSPC) would benefit more from androgen deprivation therapy (ADT) when the treatment was combined with taxane-based chemotherapy. “Identifying which patients will benefit from chemotherapy is one of the most important clinical questions in the management of metastatic prostate cancer,” Christopher Sweeney, MBBS, a cancer-specialized clinician and professor of medicine at Dana-Farber Cancer Institute, said in a press release. “The ability to identify these patients at diagnosis is a very important step towards improving patient outcomes and accelerating the inclusion of novel [treatments] into the standard of care,” Sweeney said. The data, “Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED,” were presented at the 2020 Genitourinary Cancer Symposium, held recently in San Francisco. mHSPC, also known as metastatic castration-sensitive prostate cancer (mCSPC), refers to prostate cancer that has spread to other parts of the body but still responds to androgen deprivation therapy. The goal of ADT  is to reduce the levels of male hormones, called androgens, in the body, to stop them from fueling prostate cancer cells. Even with ADT, however, this type of prostate cancer is usually associat
Subscribe or to access all post and page content.